

# Polar Characterization of Antifungal Peptides from APD2 Database

Carlos Polanco · José Lino Samaniego-Mendoza ·  
Thomas Buhse · Jorge Alberto Castañón-González ·  
Marili Leopold-Sordo

Published online: 1 July 2014  
© Springer Science+Business Media New York 2014

**Abstract** The increase in the number of pathogens due to fungi that are tolerant to therapies does not grow at the same speed than the advance on new antifungal drugs. In this sense, it is imperative to find anti-fungi peptides that are not detrimental to mammalian cells and have an effective toxicity to fungi. In this work, we use a method called polarity index, to identify anti-fungi peptides with an efficiency of 70 %. This method already published, initially identified selective antibacterial peptides from APD2 Database, and was characterized by developing a comprehensive analysis of the polar dynamics of a peptide from its linear sequence. Discriminating tests showed that in addition to being efficient in this identification, it was also good at rejecting other classifications of peptides found in that same database.

**Keywords** Polarity index method · Selective antibacterial peptides · Anti-fungi peptides

## Abbreviations

SCAAP Selective cationic amphipathic antibacterial peptides  
APD2 Antimicrobial peptide database  
QSAR Quantitative structure activity relationships

## Introduction

The anti-fungi peptides are produced by a large number of organisms, they likely arise for own protection from these pathogens as their immune response to fungal infections. The anti-fungi peptide group is the second largest in antimicrobial databases, just after antibacterial peptides. They have been experimentally isolated in mammals, bacteria, insects, and plants among others. Plants in particular are a very good source of this type of peptides [1], here a pattern has been observed in the linear sequence of the amino acid cysteine [2, 3]. However, within the anti-fungi peptides there are some that have extremely damaging action toward human beings [4–6], if we additionally consider these pathogens show a striking resistance to current antibiotics, we then have a lethal combination that will push the global health system to its limits in this decade. Today, it is not alarmist to say that these pathogens will win the battle unless we develop new drugs to tackle them, particularly anti-fungi drugs.

Undoubtedly, this scenario requires the use of tools that were unavailable 50 years ago to win the battle; we are talking about the computational-mathematical algorithms.

---

**Electronic supplementary material** The online version of this article (doi:10.1007/s12013-014-0085-3) contains supplementary material, which is available to authorized users.

---

C. Polanco (✉) · J. L. Samaniego-Mendoza ·  
J. A. Castañón-González · M. Leopold-Sordo  
Facultad de Ciencias de la Salud, Universidad Anáhuac,  
Av. Universidad Anáhuac No. 46, Col Lomas Anáhuac,  
C.P. 52786 Huixquilucan, Estado de México, Mexico  
e-mail: polanco@unam.mx

C. Polanco · J. L. Samaniego-Mendoza  
Departamento de Matemáticas, Facultad de Ciencias,  
Universidad Nacional Autónoma de México, Av. Universidad  
3000, C.P. 04510 D.F, Mexico

T. Buhse  
Centro de Investigaciones Químicas, Universidad Autónoma del  
Estado de Morelos, Av. Universidad 1001,  
C.P. 62209 Cuernavaca, Morelos, Mexico

**Table 1**  $Q[i,j]$  Polarity matrix

	P+	P–	N	NP
P+	0.0434541926	0.0218654852	0.0822031572	0.0456684195
P–	0.0260171611	0.0146692498	0.0487129800	0.0215887073
N	0.0766675919	0.0500968732	0.1873789132	0.1120952144
NP	0.0415167436	0.0224190429	0.1162468866	0.0650428981

Incidences of 88 anti-fungal peptides with unique pathogenic action extracted from the APD2 [12]

**Table 2** Polarity index method test

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
$P[i,j] + Q[i,j]$ vector of study.	(1,1)	(1,2)	(1,3)	(1,4)	(2,1)	(2,2)	(2,3)	(2,4)	(3,1)	(3,2)	(3,3)	(3,4)	(4,1)	(4,2)	(4,3)	(4,4)
Rule # 1 Polar interaction 11 is present in any of the first 9 positions	✓	✓	✓	✓	✓	✓	✓	✓	✓							
Rule # 2 Polar interaction 16 is not present in the first position	x															
Rule # 3 Polar interaction 14 is not present in any of the first five positions	x	x	x	x	x											
Rule # 4 Polar interaction 12 is not present in the 1st or 4th positions	x			x												
Rule # 5 Polar interaction 13 is not present in the 1st, 2nd, 5th, 15th or 16th positions	x	x			x										x	x
Rule # 5 Polar interaction 6 is not present in the 13th position													x			
Rule # 6 Polar interaction 3 is not present from 12th to 16th positions												x	x	x	x	x

Polarity index method rules. (✓): The polar interaction is present in the position. (x): The polar interaction is not present in the position

Based on actual experience, it seems unthinkable to calculate all possible combinatorial that can be build with small peptides, even with the current mathematical-computational algorithms there are combinatorial that is not possible to assess. Calculate yourself the peptides that can occur if you test experimentally 5 amino acids in length peptides, even for ordinary computing teams it is very complex to evaluate 13 amino acids in length peptides, the alphabet consists of 20 possible amino acids.

In such a situation, 8 years ago this research team decided to dedicate efforts to this task and build a robust algorithm that from a single physicochemical property, in this case polarity could generate a map of the initial-intermediate-final stages of a peptide, and that could display from a single reading of its amino acid linear sequence, as much information as possible about the toxic action of a peptide. The algorithm named Polarity index method [7] was previously published to effectively identify

**Table 3** Polarity index matches by pathogenic action

Number of hits	Gram+ ONLY	Gram- ONLY	Gram+ / Gram-	Virus	HIV	Fungi %	Protists %	%	Parasites	Insects	Sperms	Cancer cells	Mammalian cells	Chemotaxis	SCAAP
Unique action	81	29	119	1	0	62	70	100	3	1	0	8	4	0	6
Multiple action	213	111	518	1	0	88	1		9	2	0	20	11	0	51
	112	36	434	19	22	251	2		12	6	1	27	43	10	0
	315	149	1711	125	88	744	3		47	21	9	141	244	39	0

Polarity index matches in both groups of peptides from APD2 [12], with unique and multiple pathogenic action on: Gram+ ONLY, Gram- ONLY, Gram+/Gram-, viruses, HIV, fungi, protists, parasites, insects, carcinogenic cells, mammalian cells, sperms, and SCAAP [7–10]. Unique action: Peptides with pathogenic action against only one group. Multiple action: Peptides with pathogenic action against two or more groups. (%): Percentage of hits/total peptides

SCAAP and other groups of peptides [7–11] in the APD2 Database (<http://aps.unmc.edu/AP/> accessed December 19, 2012) [12]. In this paper, we present the results of the same method identifying anti-fungi peptides.

The fundamental thesis of this method states that the linear sequence of the peptide informs everything that is required to know in terms of its interaction with the pathogenic cell membrane, as the method requires “peptide training” with the desired profile. The method test was focused on its discriminating ability to evaluate the 14 sub-classifications of the APD2 [12] database, showing 70 % efficiency.

### Materials and Methods

Since the present work shows the identification of anti-fungi peptides from an already-published method [7], we indicate only the changes that this method requires for such identification (see Supplementary Material).

### Polarity Index Method. Updates

#### Modifications

- (i). Replacing the  $Q[i,j]$  matrix in the source program [7] by the Table 1, which represent the incidences of antifungal sequences with a unique pathogenic action. Table 1 considers 88 antifungal peptides extracted from the APD2 database [12].
- (ii). Replacing the rule in the source program [7] by  $P[i,j] + Q[i,j]$  vector complying with the next rule: the polar interaction 11 is present in any of the first nine positions, polar interaction 16 is not present in the first position, polar interaction 14 is not present in any of the first five positions, polar interaction 12 is not present in the 1st or 4th positions, polar interaction 13 is not present in the 1st, 2nd, 5th, 15th, or 16th positions, polar interaction 6 is not present in the 13th position, and polar interaction 3 is not present from 12th to 16th positions (Table 2).

#### APD2 Database Trial Data Preparation

APD2 Database [12] was classified 3636 by their *multiple* action against: 149 Gram – ONLY, 1711 Gram +/Gram– ONLY, 315 Gram + ONLY, 141 cancer cells, 9 sperms, 88 HIV, 744 fungi, 21 insects, 244 mammalian cells, 47 parasites, 3 protists, 39 chemotaxis, 0 SCAAP, 125 virus; and also 1059 by their *unique* action against: 111 Gram – ONLY, 213 Gram + ONLY, 518 Gram +/Gram– ONLY,

**Table 4** Polarity index matches by linear sequence in fungi

No.	PUBMED ID	Sequence	Cytotoxicity	#1	Reference
1	16126239	AGECVQGRCPGSMCCSQFGYCGRGPKYCGR	11–904		[13]
2	12856109	AKYTGKCTKSKNECKYKNDAGKDTFIKCPKF DNKKCTKDNNKCTVDTYNNAVDCD	1–50		[14]
3	17883246	APPGARPPP PPPPPPPPPG	7–111	N	[15]
4	12644678	ATCKAECPTWDSVCINKKPCVACCKKAKFS DGHCSKILRRCLCTKEC	10		[16]
5	7893713	ATYNGKCYKKDNICKYKAQSGKTAICKCY VKKCPRDGAKCEFDYSY KGKCYC	NF		[17]
6	17994764	AVRIGPCDQVCPRIUPERHECCRAHGRSG YAYCSGGMYCN	NF		[18]
7	14661954	CIANRNGCQPDGSGNCCSGYCHKEPGWVAGYCR	64		[19]
8	14661954	CIKNGNGCQPDGSGNCCSRYCHKEPGWVAGYCR	64		[19]
9	14661954	CIKNGNGCQPNQSGNCCSGYCHKQPGWVAGYCRRK	8–16		[19]
10	18212107	CLAGRLDKQCTCRRSQPSRRSGHEVGRP SPHCGPSRQCGCHMD	29–237		[20]
11	17272268	DEKGPKWKR	35	N	[21]
12	7628617	DGVKLCDVPSGTWSGHCSSSKCSQCKDREHFA YGGACHYQFPSVKCFCKRQC	1–30		[22]
13	11580275	DKLIGSCVWGA VNYTSDCNAGECKRRGY KGGHCGSFANVNCWET	0.4–4		[23]
14	14978308	DKLIGSCVWGA VNYT SNCNAECKRRG YKGGHCGSFANVNCW	6–12		[24]
15	10571855	DPQTECQQCQRRRCRQESGPRQQYCY QRRCKEICEEEEEYN	25		[25]
16	2303595	DSHAKRHHGYKRKFHEKHSHRGRY	NF	N	[26]
17	20423320	DSHEERRQGRHGHHEYGRKFHEKHSHRGRY	NF		[27]
18	20423320	DSHEKRHHEHRRKFHEKHSHRGRY	NF	N	[27]
19	14728668	DTLIGSCVWGATNYTSDCNACKR RGYKGGHCGSFLNVNCWCE	7–236		[28]
20	22497806	EGPVGLADPDGPASAPLGP	3–22	N	[29]
21	17375322	ELCEKASQTWSGTCGKTKHCDDQCK SWEGAAHGACHVRDGHKMCFCYFNC	50–1000		[30]
22	12859949	ELPKLPDDKVLIRSRSNCPKGV WNGFDCKSPFAFS	65–522	N	[31]
23	7947977	EQCGRQAGGKLCPNLCCSQYGWCG SSDDYCSPSKNCQSNCKGGG	NF		[32]
24	12067732	ETCASRCPRPCNAGLCCSIYGYCGSG AAYCGAGNCRQCRCG	18–109		[33]
25	12067732	ETCASRCPRPCNAGLCCSIYGYC GSGNAYCGAGNCRQCRCG	35–155		[33]
26	11087945	FFPNVASVPGQVLLKKIFCAISKKC	NF	N	[34]
27	17272268	GFSPNLPGKGLRIS	50		[21]
28	18797515	GHHPHGHHPHGHHPHGHHHPH	0.07–14		[35]
29	16330099	GIMDSVKGVAKNLAAKLEKLKCKITGC	73	N	[36]
30	16330099	GLLSSFKGVAKVAKDLAGKLEKLKCKITGC	10–164	N	[36]
31	19857508	GRILSFIKGLAEHL	0.5–50	N	[37]
32	12644678	GTCKAECPTWEGICINKAPCVKCC KAQPEKFTDGHCSKILRRCLCTKPC	NF		[16]
33	12811766	GVTITVKPPFPQCVFYECIANC RSRGYKNGGYCTINGCQLR	275		[38]

**Table 4** continued

No.	PUBMED ID	Sequence	Cytotoxicity	#1	Reference
34	2104802	GWLRKLGKKIERIGQHTRDASI QVLGIAQQAANVAATAR	10		[39]
35	18618271	HTPTPTPICKSRSEYKGRCIQDMDCNAACV KESESYTGGFCNGRPPFKQCF CTKPCKRERAAATLRWPGL	80–159		[40]
36	12138110	ICIFCCGCCHRSKCGMCCCT	NF		[41]
37	19857508	ILGIITSLKSLGKK	0.5–50		[37]
38	21167915	ITCQQVTSELGPCVPYLTGQGIP	100–400		[42]
39	9435139	KDCKTESNTFPGICITKPPCRKACI KEKFTDGHCSKILRRCLCTKPC	NF		[43]
40	19857508	KDLHTVVSAILQAL	0.5–50	N	[37]
41	21056078	KICERASGTWKGICIHNSDCNNQCV KWENAGSGSCHYQFPNYMCFYFDC	2–6		[44]
42	21056078	KICERASGTWKGICIHNSDCNNQCV KWENAGSGSCHYQFPNYMCFYFNC	2–6		[44]
43	8422949	KLCERPSGTWSGVCGNNAACKNQCI NLEKARHGSCNYVFPAAHKCICYFPC	25–100		[45]
44	8422949	KLCERPSGTWSGVCGNSNACKNQICIN LEKARHGSCNYVFPAAHKCICYFPC	35–100		[45]
45	8422949	KLCERSSGTWSGVCGNNAACKNQICIN LEGARHGSCNYVFPYHRCICYFPC	19–100		[45]
46	8422949	KLCQRPSGTWSGVCGNNAACKNQICIN LEKARHGSCNYVFPAAHKCICYFPC	4–100		[45]
47	18241956	KQQLATEAESAGPIL	15	N	[46]
48	10571855	KRDPQREYEDCRRRCEQQEPRQQ HQCQLRCREQQRQHGRG GDMMPQRGGSGRYEEGEEEQS	25		[47]
49	9435139	KSTCKAESNTFPGLCITKPPCRKACL SEKFTDGGKCSKILRRCICYKPC	NF	N	[43]
50	10860545	KTCEHLADTYRGCFTNASCDDHC KNKAHLISGTCHNWKCFCTQNC	0.04–100	N	[48]
51	18786582	KTCENLADTYKGPCFTTGSCD	25–100		[49]
52	10860545	KTCENLSGTFKGPCIPDGNCNKHCRN NEHLLSGRCRDDFRCWCTNRC	0.34–100	N	[48]
53	2103443	KTCENLVDTYRGCFTTGSCDDHCKN KEHLLSGRCRDDVRCWCTRNC	NF	N	[50]
54	10591099	LCNERPSQTWSGNGGNTAHCDKQCQ DWEKASHGACHKRENHWKCFYFNC	NF		[51]
55	21736910	LMCTHPLDCSN	4–32		[52]
56	19914321	LSKFGGECSLKHNTCTYLKGGKNHVNCGSAA NKKCKSDRRHCEYDEHHKRVDQCPTV	NF		[53]
57	10601197	MINRTDCNENSYLEIHNNEGRDTLCFANA GTMPVAIYGVNWWESGNNVTLQFQRN LSDPRLETITLQKWGSWNPGLIHEILSIRIY	20–150	N	[54]
58	NO	NEMGGPLVVEARTCESQSHKFKGTCL SDTNCANVCHSERFSGGKCRGFRRRCFCTTHC	NF	N	[55]
59	1799696	NTCENLAGSYKGVCFGGCDRHR TQEGAISGRCDDFRCWCTKNC	NF	N	[56]
60	7647301	QICKAPSQTFPGLCFMDSSCRKY CIKEKFTGGHCSKLQRKCLCTKPC	NF		[57]
61	22032337	QKLCERPSGTWSGVCGNNGACRNQ CIRLERARHGSCNYVFPAAHKCICYFPC	5–20		[58]
62	8422949	QKLCERPSGTWSGVCGNNAACKN QCINLEKARHGSCNYVFPAAHKCICYFPC	70–100		[59]

**Table 4** continued

No.	PUBMED ID	Sequence	Cytotoxicity	#1	Reference
63	22032337	QKLCERPSGTWSGVCNNACRNQ CINLEKARHGSCNYVFPAAHKCICYFPC	10–15		[58]
64	7780308	QKLCERSSGTWSGVCNNACKNQ CINLEGARHGSCNYIFPYHRCICYFPC	5–11		[60]
65	8422949	QKLCQRPSGTWSGVCNNACKNQ LEKARHGSCNYVFPAAHKCICYFPC	5–100		[59]
66	10447467	QNNICKTTSKHFGLCFADSKCRKVICQEDK FEDGHCSKLQRKCLCTKNC	NF		[61]
67	9507071	QQCGRQASGRLCGNRLCCSQWGYCGSTA SYCGAGCQSQR	0.6–7		[62]
68	20626828	RECKAQGRHGTCFRDANCVQVCEKQA GWSHGDCRAQFKCKCIFEC	5–20		[63]
69	1495489	RECKTESNTFPGICITKPPCRKACISEKF TDGHCSKLLRRCLCTKPC	NF		[64]
70	18618271	RHRHCFSQSHKFGVACLRESNCENV CKTEGFPSGECKWHGIVSKCHCKRIC	6–117		[65]
71	11451958	RILSILRHQNLKELQDLAL	12–119	N	[66]
72	1528633	RKFHEKHHSREPFYGDYGSNYLYDN	NF		[67]
73	1528633	RKFHEKHHSRGRYSNYLYDN	NF	N	[67]
74	2303595	RKFHEKHHSRGRY	NF	N	[26]
75	2303595	RKFHEKHHSRGRY	NF		[26]
76	10571855	RQRDPQQYEQCKKQRRETEPRHMQ TCQQRCEERYEKEKRKQKRY EEQREDEEKYEERMKEEDN	2–50		[68]
77	11101813	RTCENLADKYRGPFCGCDTHCT TKENAVSGRCRDDFRWCWKRC	NF		[69]
78	18611251	RTCESQSHRFKGTVCVRQSNCAAV CQTEGFHGGNCRGFRRCFCTKHC	6–20		[70]
79	1995329	RVCMKGSAGFKGLCMRDQNAQV CLQEGWGGNCDGVMRQCKCIRQC	NF	N	[71]
80	9715910	RVCMKGSQHHSFPCISDRCSNECVKEE GGWTAGYCHLRYCRCQKAC	NF		[72]
81	22032337	RYCERSSGTWSGVCNSGKCSNQCQRLE GAAHGSCNYVFPAAHKCICYPC	25	N	[58]
82	22032337	RYCERSSGTWSGVCNTDKCSSQCQRL EGAAHGSCNYVFPAAHKCICYPC	20–25	N	[58]
83	18618271	RYCLSQSHRFKGLCMSSNCANVCQT ENFPGGECKADGATRKCFCKKIC	5–11		[65]
84	10512732	SKYGGECVVEHNTCTYLKGGKDHI SCPSAANLRCKTERHHCEYDEHHKTVDQCQTPV	26–96		[73]
85	18943919	SYFSAWAGPGCNNHNARYSKCGCSNIG HNVHGGYEFVYQQTAAAYNTDNCK GVAQTRFSSSVNQACSNFGWKSVEFIQC	NF		[74]
86	23193597	TFPKCAPTRPPGPKPCDINNFKSKFWHIWRA	4	N	[75]
87	20721297	VTCDVLSFEAKGIAVNHSACALHCIAL RKKGGSCQNGVCVRN	4–8		[76]
88	8535393	YGPGDGHGGGGHGGGGHGGGGHGGGGH GHGPGGGFGGGHGGGGHGGGGHGGGGH GGGGSPGHGAGGGYPGGHGGGGHGGGYQTHGY	NF	N	[77]

Subject sequences identified by polarity index method in APD2 database <http://aps.unmc.edu/AP/> accessed December 19, 2012 [12], where peptides have action only on fungi. #1: (N) peptides not accepted by polarity index method. Source: National Center for Biotechnology Information, U.S. National Library of Medicine <http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins> in database: Swiss-Prot (swissprot), accessed March 20, 2013. Cytotoxicity: the concentration ( $\mu\text{g}/\text{mL}$ ) required for inhibiting the growth of mammalian cells, usually red blood cells or fibroblasts. NF: The toxicity report was not found

20 cancer cells, 0 HIV, 88 fungi, 35 H1N1, 2 insects, 11 mammalian cells, 9 parasites, 1 protists, 0 chemotaxis, 30 SCAAP, 0 sperms, and 21 virus. The classification of single-acting peptides, took place checking all peptide occurrences in all groups.

## Results

The computational mathematical method described here was evaluated with the APD2 database [12] ranked by single and multiple action peptides, showing the following results:

It showed over  $62/88 = 70\%$  efficiency detecting antifungal peptides in all APD2 database sub-classifications (Table 3, column Fungi), and  $1/1 = 100\%$  detecting anti-protists (Table 3, column Protists). Similarly, it is observed that in the remaining groups of the same database, the method does not identify false positives by more than  $26/88 = 30\%$  (Table 4, entries with N-letter). The method does not establish a significant difference with regard to their toxicity (Table 4, column Cytotoxicity), as it does not differentiate the most toxic from the least toxic.

## Discussion

The re-emergence of pathogens resistant to many antibiotics must be an alarm signal to trigger their combat with multidisciplinary procedures, under this idea we could think that the identification of anti-fungi peptides should be aimed toward the design of algorithms that include diverse factors. The thesis of this work focuses only on the linear sequence of the peptide as the main source of the peptide toxic action. This does not mean that the lipid aqueous medium or cell membrane has no influence, in fact, we consider they are important as our algorithm uses “training peptides” with the desired profile. From this perspective, we can say that this method, in its identification of anti-fungi peptides is inclusive of these and other factors as yet unidentified. So far, we have found that one of the factors relate to the toxic profile of the peptide. Polarity index method informs extensively and in detail about the polar profile and the electro-negativity of the peptide, but in a different way than conventional algorithms do, as the polarity matrix reports every possible polar interaction, providing a dynamic and also a static profile of the peptide.

Furthermore, many algorithms designed for anti-fungi identification generate a single element which represents little information, in comparison with the 16 elements provided by the matrix of our polarity method. The method has already been used for the efficient identification of SCAAP [7] and prebiotic analysis [11] due to its

robustness; however, we consider the method is not efficient enough identifying the most toxic anti-fungi peptides, which means we have to improve its search profile. With this in mind, we have sub-classified the groups located in APD2 database [12] from 9 to 14 groups ([7] Table 3), and in this sense we make sure the method remains exclusive.

On the basis of the above, we believe this method is a reliable filter of anti-fungi peptides as it reduces considerably the number of experimental trials; it can also be used to know how nature constructs these peptides and utilize this information to perfect the search profile to find peptides more toxic to pathogens.

## Conclusions

In summary, we report an implementation of a polarity index method in the prediction of anti-fungal peptides from APD2 database, with high level of discriminative efficiency ( $63/89 = 70\%$ ), from single physicochemical feature, polarity.

**Acknowledgments** The authors acknowledge the Departamento de Cómputo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán for support, and the proof-reading of this manuscript by Concepción Celis Juárez.

**Conflict of interest** We declare that we do not have any financial and personal interest with other people or organizations that could inappropriately influence (bias) our work.

## References

- Rutala, W. A., Barbee, S. L., Aguiar, N. C., Sobsey, M. D., & Weber, D. J. (2000). Antimicrobial activity of home disinfectants and natural products against potential human pathogens. *Infection Control and Hospital Epidemiology*, *21*(1), 33–38.
- Mello, E. O., Ribeiro, S. F., Carvalho, A. O., Santos, I. S., Da Cunha, M., Santa-Catarina, C., et al. (2011). Antifungal activity of PvD1 defensin involves plasma membrane permeabilization, inhibition of medium acidification, and induction of ROS in fungi cells. *Current Microbiology*, *62*(4), 1209–1217.
- Fridkin, S. K., & Jarvis, W. R. (1996). Epidemiology of nosocomial fungal infections. *Clinical Microbiology Reviews*, *9*(4), 499–511.
- Powderly, W. G., Mayer, K. H., & Perfect, J. R. (1999). Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. *AIDS Research and Human Retroviruses*, *15*(16), 1405–1412.
- Rippon, J. W. (1988). *Medical mycology* (3rd ed.). Philadelphia: WB Saunders Co.
- Law, D., Moore, C. B., Joseph, L. A., Keaney, M. G., & Denning, D. W. (1996). High incidence of antifungal drug resistance in *Candida tropicalis*. *International Journal of Antimicrobial Agents*, *7*(4), 241–245.
- Polanco, C., Samaniego, J. L., Buhse, T., Mosqueira, F. G., Negron-Mendoza, A., Ramos-Bernal, S., et al. (2012). Characterization of selective antibacterial peptides by polarity index. *International Journal of Peptides*. doi:10.1155/2012/585027.

8. Polanco González, C., Nuño Maganda, M. A., Arias-Estrada, M., & del Rio, G. (2011). An FPGA implementation to detect selective cationic antibacterial peptides. *PLoS One*, 6(6), e21399.
9. Polanco, C., & Samaniego, J. L. (2009). Detection of selective cationic amphipathic antibacterial peptides by Hidden Markov models. *Acta Biochimica Polonica*, 56, 167–176.
10. del Rio, G., Castro-Oregon, S., Rao, R., Ellerby, H. M., & Bredesen, D. E. (2001). APAP, a sequence-pattern recognition approach identifies substance P as a potential apoptotic peptide. *FEBS Letters*, 3, 213–219.
11. Polanco, C., Buhse, T., Samaniego, J. L., & Castañón González, J. A. (2013). A toy model of prebiotic peptide evolution: the possible role of relative amino acid abundances. *Acta Biochimica Polonica*, 60(2), 175–182.
12. Wang, G., Li, X., & Wang, Z. (2009). APD2: the updated antimicrobial peptide database and its application in peptide design. *Nucleic Acids Research*, 37, D933–D937.
13. Lipkin, A., Anisimova, V., Nikonorova, A., Babakov, A., Krause, E., Bienert, M., et al. (2005). An antimicrobial peptide Ar-AMP from amaranth (*Amaranthus retroflexus* L.) seeds. *Phytochemistry*, 66(20), 2426–2431.
14. Kaiserer, L., Oberparleiter, C., Weiler-Görz, R., Burgstaller, W., Leiter, E., & Marx, F. (2003). Characterization of the *Penicillium chrysogenum* antifungal protein PAF. *Archives of Microbiology*, 180(3), 204–210.
15. Cabras, T., Longhi, R., Secundo, F., Nocca, G., Conti, S., Polonelli, L., et al. (2008). Structural and functional characterization of the porcine proline-rich antifungal peptide SP-B isolated from salivary gland granule. *Journal of Peptide Science*, 14(3), 251–260.
16. Lay, F. T., Brugliera, F., & Anderson, M. A. (2003). Isolation and properties of floral defensins from ornamental tobacco and petunia. *Plant Physiology*, 131(3), 1283–1293.
17. Campos-Olivas, R., Bruix, M., Santoro, J., Lacadena, J., Martinez del Pozo, A., Gavilanes, J. G., et al. (1995). NMR solution structure of the antifungal protein from *Aspergillus giganteus*: evidence for cysteine pairing isomerism. *Biochemistry*, 34(9), 3009–3021.
18. Kouno, T., Mizuguchi, M., Tanaka, H., Yang, P., Mori, Y., Shinoda, H., et al. (2007). The structure of a novel insect peptide explains its Ca<sup>2+</sup> channel blocking and antifungal activities. *Biochemistry*, 46(48), 13733–13741.
19. Barbault, F., Landon, C., Guennegues, M., Meyer, J. P., Schott, V., Dimarcq, J. L., et al. (2003). Solution structure of Alo-3: a new knottin-type antifungal peptide from the insect *Acrocis longimanus*. *Biochemistry*, 42(49), 14434–14442.
20. Simon, A., Kullberg, B. J., Tripet, B., Boerman, O. C., Zeeuwen, P., van der Ven-Jongekrijg, J., et al. (2008). Drosomycin-like defensin, a human homologue of *Drosophila melanogaster* drosomycin with antifungal activity. *Antimicrobial Agents and Chemotherapy*, 52(4), 1407–1412.
21. Li, J., Xu, X., Xu, C., Zhou, W., Zhang, K., Yu, H., et al. (2007). Anti-infection peptidomics of amphibian skin. *Molecular and Cellular Proteomics*, 6(5), 882–894.
22. Osborn, R. W., De Samblanx, G. W., Thevissen, K., Goderis, I., Torrekens, S., Van Leuven, F., et al. (1995). Isolation and characterisation of plant defensins from seeds of Asteraceae, Fabaceae, Hippocastanaceae and Saxifragaceae. *FEBS Letters*, 368(2), 257–262.
23. Lamberty, M., Caille, A., Landon, C., Tassin-Moindrot, S., Hetru, C., Bulet, P., et al. (2001). Solution structures of the antifungal heliomicin and a selected variant with both antibacterial and antifungal activities. *Biochemistry*, 40(40), 11995–12003.
24. Landon, C., Guennegues, M., Barbault, F., Legrain, M., Menin, L., Schott, V., et al. (2004). Lead optimization of antifungal peptides with 3D NMR structures analysis. *Protein Science*, 13(3), 703–713.
25. Marcus, J. P., Green, J. L., Goulter, K. C., & Manners, J. M. (1999). A family of antimicrobial peptides is produced by processing of a 7S globulin protein in *Macadamia integrifolia* kernels. *Plant J*, 19(6), 699–710.
26. Troxler, R. F., Offner, G. D., Xu, T., Vanderspek, J. C., & Oppenheim, F. G. (1990). Structural relation between human salivary histatins. *Journal of Dental Research*, 69(1), 2–6.
27. Padovan, L., Segat, L., Pontillo, A., Antcheva, N., Tossi, A., & Crovella, S. (2010). Histatins in non-human primates: gene variations and functional effects. *Protein and Peptide Letters*, 17(7), 909–918.
28. Lee, Y. S., Yun, E. K., Jang, W. S., Kim, L., Lee, J. H., Park, S. Y., et al. (2004). Purification, cDNA cloning and expression of an insect defensin from the great wax moth *Galleria mellonella*. *Insect Mol Biol*, 13(1), 65–72.
29. Xiao, Y., Meng, F., Qiu, D., & Yang, X. (2012). Two novel antimicrobial peptides purified from the symbiotic bacteria *Xenorhabdus budapestensis* NMC-10. *Peptides*, 35(2), 253–260.
30. de Zélicourt, A., Letousey, P., Thoiron, S., Campion, C., Simoneau, P., Elmorjani, K., et al. (2007). Ha-DEF1, a sunflower defensin, induces cell death in *Orobanche* parasitic plants. *Planta*, 226(3), 591–600.
31. Tomie, T., Ishibashi, J., Furukawa, S., Kobayashi, S., Sawahata, R., Asaoka, A., et al. (2003). Scarabaecin, a novel cysteine-containing antifungal peptide from the rhinoceros beetle, *Oryctes rhinoceros*. *Biochemical and Biophysical Research Communication*, 307(2), 261–266.
32. Soedjanaatmadja, U. M., Hofsteenge, J., Jeronimus-Stratingh, C. M., Bruins, A. P., & Beintema, J. J. (1994). Demonstration by mass spectrometry that pseudo-hevein and hevein have ragged C-terminal sequences. *Biochimica et Biophysica Acta*, 1209(1), 144–148.
33. Huang, R. H., Xiang, Y., Liu, X. Z., Zhang, Y., Hu, Z., & Wang, D. C. (2002). Two novel antifungal peptides distinct with a five-disulfide motif from the bark of *Eucommia ulmoides* Oliv. *FEBS Letters*, 521(1–3), 87–90.
34. Basir, Y. J., Knoop, F. C., Dulka, J., & Conlon, J. M. (2000). Multiple antimicrobial peptides and peptides related to bradykinin and neuromedin N isolated from skin secretions of the pickerel frog, *Rana palustris*. *Biochimica et Biophysica Acta*, 1543(1), 95–105.
35. Rydengård, V., Shannon, O., Lundqvist, K., Kacprzyk, L., Chalupka, A., Olsson, A. K., et al. (2008). Histidine-rich glycoprotein protects from systemic *Candida* infection. *PLoS Pathogens*, 4(8), e1000116.
36. Rollins-Smith, L. A., Woodhams, D. C., Reinert, L. K., Vredenburg, V. T., Briggs, C. J., Nielsen, P. F., et al. (2006). Antimicrobial peptide defenses of the mountain yellow-legged frog (*Rana muscosa*). *Developmental and Comparative Immunology*, 30(9), 831–842.
37. Baek, J. H., & Lee, S. H. (2010). Isolation and molecular cloning of venom peptides from *Orancistrocerus drewseni* (Hymenoptera: Eumenidae). *Toxicon*, 55(4), 711–718.
38. Schuhmann, B., Seitz, V., Vilcinskas, A., & Podsiadlowski, L. (2003). Cloning and expression of gallerimycin, an antifungal peptide expressed in immune response of greater wax moth larvae, *Galleria mellonella*. *Archives of Insect Biochemistry Physiology*, 53(3), 125–133.
39. Kylsten, P., Samakovlis, C., & Hultmark, D. (1990). The cecropin locus in *Drosophila*; a compact gene cluster involved in the response to infection. *EMBO Journal*, 9(1), 217–224.
40. De-Paula, V. S., Razzera, G., Medeiros, L., Miyamoto, C. A., Almeida, M. S., Kurtenbach, E., et al. (2008). Evolutionary



- relationship between defensins in the Poaceae family strengthened by the characterization of new sugarcane defensins. *Plant Molecular Biology*, 68(4–5), 321–335.
41. Hunter, H. N., Fulton, D. B., Ganz, T., & Vogel, H. J. (2002). The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. *Journal of Biological Chemistry*, 277(4), 37597–37603.
  42. Zottich, U., Da Cunha, M., Carvalho, A. O., Dias, G. B., Silva, N. C., Santos, I. S., et al. (2011). Purification, biochemical characterization and antifungal activity of a new lipid transfer protein (LTP) from *Coffea canephora* seeds with  $\alpha$ -amylase inhibitor properties. *Biochimica et Biophysica Acta*, 1810(4), 375–383.
  43. Yamada, S., Komori, T., Myers, P. N., Kuwata, S., Kubo, T., & Imaseki, H. (1997). Expression of plasma membrane water channel genes under water stress in *Nicotiana excelsior*. *Plant and Cell Physiology*, 38(11), 1226–1231.
  44. Slavokhotova, A. A., Odintsova, T. I., Rogozhin, E. A., Musolyamov, A. K., Andreev, Y. A., Grishin, E. V., et al. (2011). Isolation, molecular cloning and antimicrobial activity of novel defensins from common chickweed (*Stellaria media* L.) seeds. *Biochimie*, 93(3), 450–456.
  45. Terras, F. R., Torrekens, S., Van Leuven, F., Osborn, R. W., Vanderleyden, J., Cammue, B. P., et al. (1993). A new family of basic cysteine-rich plant antifungal proteins from Brassicaceae species. *FEBS Letters*, 316(3), 233–240.
  46. Zhang, B., Xie, C., & Yang, X. (2008). A novel small antifungal peptide from *Bacillus* strain B-TL2 isolated from tobacco stems. *Peptides*, 29(3), 350–355.
  47. Marcus, J. P., Green, J. L., Goulter, K. C., & Manners, J. M. (1999). A family of antimicrobial peptides is produced by processing of a 7S globulin protein in *Macadamia integrifolia* kernels. *The Plant Journal*, 19(6), 699–710.
  48. Almeida, M. S., Cabral, K. M., Zingali, R. B., & Kurtenbach, E. (2000). Characterization of two novel defense peptides from pea (*Pisum sativum*) seeds. *Archives of Biochemistry and Biophysics*, 378(2), 278–286.
  49. Games, P. D., Dos Santos, I. S., Mello, E. O., Diz, M. S., Carvalho, A. O., de Souza-Filho, G. A., et al. (2008). Isolation, characterization and cloning of a cDNA encoding a new antifungal defensin from *Phaseolus vulgaris* L. seeds. *Peptides*, 29(12), 2090–2100.
  50. Ishibashi, N., Yamauchi, D., & Minamikawa, T. (1990). Stored mRNA in cotyledons of *Vigna unguiculata* seeds: nucleotide sequence of cloned cDNA for a stored mRNA and induction of its synthesis by precocious germination. *Plant Molecular Biology*, 15(1), 59–64.
  51. Fant, F., Vranken, W. F., & Borremans, F. A. (1999). The three-dimensional solution structure of *Aesculus hippocastanum* antimicrobial protein 1 determined by 1H nuclear magnetic resonance. *Proteins*, 37(3), 388–403.
  52. Mandal, S. M., Migliolo, L., Franco, O. L., & Ghosh, A. K. (2011). Identification of an antifungal peptide from *Trapa natans* fruits with inhibitory effects on *Candida tropicalis* biofilm formation. *Peptides*, 32(8), 1741–1747.
  53. Rodríguez-Martín, A., Acosta, R., Liddell, S., Núñez, F., Benito, M. J., & Asensio, M. A. (2010). Characterization of the novel antifungal protein PgAFP and the encoding gene of *Penicillium chrysogenum*. *Peptides*, 31(4), 541–547.
  54. Bormann, C., Baier, D., Horr, I., Raps, C., Berger, J., Jung, G., et al. (1999). Characterization of a novel, antifungal, chitin-binding protein from *Streptomyces tendae* Tu901 that interferes with growth polarity. *Journal of Bacteriology*, 181(24), 7421–7429.
  55. Urdangarin, M. C., Sigrid, N., Broekaert, W., & de la Canal, L. (2000). A defensin gene expressed in sunflower inflorescence. *Plant Physiology and Biochemistry*, 38(3), 253–258.
  56. Chiang, C. C., & Hadwiger, L. A. (1991). The *Fusarium solani*-induced expression of a pea gene family encoding high cysteine content proteins. *Molecular Plant-Microbe Interactions*, 4(4), 324–331.
  57. Milligan, S. B., & Gasser, C. S. (1995). Nature and regulation of pistil-expressed genes in tomato. *Plant Molecular Biology*, 28(4), 691–711.
  58. de Beer, A., & Vivier, M. A. (2011). Four plant defensins from an indigenous South African Brassicaceae species display divergent activities against two test pathogens despite high sequence similarity in the encoding genes. *BMC Research Notes*, 4(1), 459.
  59. Terras, F. R. G., Torrekens, S., Van Leuven, F., Osborn, R. W., Vanderleyden, J., Cammue, B. P., et al. (1993). A new family of basic cysteine-rich plant antifungal proteins from Brassicaceae species. *FEBS Letters*, 316(3), 233–240.
  60. Terras, F. R., Eggermont, K., Kovaleva, V., Raikhel, N. V., Osborn, R. W., Kester, A., et al. (1995). Small cysteine-rich antifungal proteins from radish: their role in host defense. *Plant Cell*, 7(5), 573–588.
  61. Aluru, M., Curry, J., & O'Connell, M. A. (1999). The electronic plant gene register. *Plant Physiology*, 120(2), 633–635.
  62. Koo, J. C., Lee, S. Y., Chun, H. J., Cheong, Y. H., Choi, J. S., Kawabata, S. I., et al. (1998). Two hevein homologs isolated from the seed of *Pharbitis nil* L. exhibit potent antifungal activity. *Biochimica et Biophysica Acta*, 1382(1), 80–90.
  63. Portieles, R., Ayra, C., Gonzalez, E., Gallo, A., Rodriguez, R., Chacón, O., et al. (2010). NmDef02, a novel antimicrobial gene isolated from *Nicotiana megalosiphon* confers high-level pathogen resistance under greenhouse and field conditions. *Plant Biotechnology Journal*, 8(6), 678–690.
  64. Gu, Q., Kawata, E. E., Morse, M. J., Wu, H. M., & Cheung, A. Y. (1992). A flower-specific cDNA encoding a novel thionin in tobacco. *Molecular and General Genetics*, 234(1), 89–96.
  65. De-Paula, V. S., Razzera, G., Medeiros, L., Miyamoto, C. A., Almeida, M. S., Kurtenbach, E., et al. (2008). Evolutionary relationship between defensins in the Poaceae family strengthened by the characterization of new sugarcane defensins. *Plant Molecular Biology*, 68(4–5), 321–335.
  66. Lugardon, K., Chasserot-Golaz, S., Kieffer, A. E., Maget-Dana, R., Nullans, G., Kieffer, B., et al. (2001). Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47–66)-derived peptide. *Journal of Biological Chemistry*, 276(38), 35875–35882.
  67. Xu, L., Lal, K., & Pollock, J. J. (1992). Histatins 2 and 4 are autolytic degradation products of human parotid saliva. *Oral Microbiology and Immunology*, 7(2), 127–128.
  68. Marcus, J. P., Green, J. L., Goulter, K. C., & Manners, J. M. (1999). A family of antimicrobial peptides is produced by processing of a 7S globulin protein in *Macadamia integrifolia* kernels. *The Plant Journal*, 19(6), 699–710.
  69. Gao, A. G., Hakimi, S. M., Mittanck, C. A., Wu, Y., Woerner, B. M., Stark, D. M., et al. (2000). Fungal pathogen protection in potato by expression of a plant defensin peptide. *Nature Biotechnology*, 18(12), 1307–1310.
  70. de Beer, A., & Vivier, M. A. (2008). Vv-AMP1, a ripening induced peptide from *Vitis vinifera* shows strong antifungal activity. *BMC Plant Biology*, 8(1), 75.
  71. Bloch, C. Jr., & Richardson, M. (1991). A new family of small (5 kDa) protein inhibitors of insect alpha-amylases from seeds or sorghum (*Sorghum bicolor* (L.) Moench) have sequence homologies with wheat gamma-purothionins. *FEBS Letters*, 279(1), 101–104.
  72. Bloch, C. Jr., Patel, S. U., Baud, F., Zvelebil, M. J., Carr, M. D., Sadler, P. J., et al. (1998). 1H NMR structure of an antifungal gamma-thionin protein Slalpha1: similarity to scorpion toxins. *Proteins*, 32(3), 334–349.

73. Gun Lee, D., Shin, S. Y., Maeng, C. Y., Jin, Z. Z., Kim, K. L., & Hahm, K. S. (1999). Isolation and characterization of a novel antifungal peptide from *Aspergillus niger*. *Biochemical and Biophysical Research Communications*, 263(3), 646–651.
74. Ekramoddoullah, A. K., Liu, J. J., & Zamani, A. (2006). Cloning and Characterization of a Putative Antifungal Peptide Gene (Pm-AMP1) in *Pinus monticola*. *Phytopathology*, 96(2), 164–170.
75. Mandal, S. M. (2012). A novel hydroxyproline rich glycopeptide from pericarp of *Datura stramonium*: proficiently eradicate the biofilm of antifungals resistant *Candida albicans*. *Biopolymers*, 98(4), 332–337.
76. Hwang, J. S., Lee, J., Kim, Y. J., Bang, H. S., Yun, E. Y., Kim, S. R., et al. (2009). Isolation and Characterization of a Defensin-Like Peptide (Coprinsin) from the Dung Beetle, *Copris tripartitus*. *International Journal of Peptides*. doi:10.1155/2009/136284.
77. Lee, S. Y., Moon, H. J., Kurata, S., Natori, S., & Lee, B. L. (1995). Purification and cDNA cloning of an antifungal protein from the hemolymph of *Holotrichia diomphalia* larvae. *Biological & Pharmaceutical Bulletin*, 18(8), 1049–1052.